BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
May 06, 2002
 |  BioCentury  |  Emerging Company Profile

Trigen: Making better (thrombin) time

Therapeutic agents used to prevent and treat thromboembolic disease include unfractionated heparin, low molecular weight heparin and warfarin. Although efficacious, these intravenous anticoagulants are not without limitations. Trigen Holdings plc was founded on research performed at the Thrombosis Research Institute (TRI) in London that seeks to address some of the limitations of marketed drugs, including route of administration and the risk of bleeding.

Trigen has focused its discovery efforts in atheroma and thrombosis. Atheroma is a process where arteries become hardened and narrowed, leading to chronic arterial disease. As atheroma progresses, the risk of thrombosis increases. Thrombosis is an acute event, where the blood flow is blocked when atheromatous plaque breaks off from the surface of an artery, which causes release of thrombotic factors.

Trigen's lead compound, TRI50b, is a thrombin inhibitor. "Thrombin is a key enzyme low down in the coagulation cascade. If you inhibit thrombin you'll see...

Read the full 734 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >